An exploratory clinical study on the safety of combination therapy with effector cell therapy and immune checkpoint inhibitors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2018
At a glance
- Drugs Immunotherapies (Primary) ; Nivolumab (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 22 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 18 Oct 2017 Status changed from not yet recruiting to recruiting.
- 24 Aug 2017 New trial record